NASDAQ:XOMA XOMA (XOMA) Stock Price, News & Analysis → Your vote doesn’t matter (From The Freeport Society) (Ad) Free XOMA Stock Alerts $26.00 +0.99 (+3.96%) (As of 12:30 PM ET) Add Compare Share Share Today's Range$24.95▼$26.5450-Day Range$23.29▼$26.5052-Week Range$13.48▼$27.00Volume6,620 shsAverage Volume17,831 shsMarket Capitalization$302.64 millionP/E RatioN/ADividend YieldN/APrice Target$57.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get XOMA alerts: Email Address XOMA MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside127.9% Upside$57.00 Price TargetShort InterestBearish2.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.22Upright™ Environmental ScoreNews Sentiment0.90Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector266th out of 913 stocksPharmaceutical Preparations Industry122nd out of 429 stocks 3.5 Analyst's Opinion Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXOMA has only been the subject of 3 research reports in the past 90 days.Read more about XOMA's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.30% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 18.8, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently increased by 9.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for XOMA is -0.22. Previous Next 2.7 News and Social Media Coverage News SentimentXOMA has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for XOMA this week, compared to 1 article on an average week.MarketBeat Follows4 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.76) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About XOMA Stock (NASDAQ:XOMA)XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More XOMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XOMA Stock News HeadlinesJune 12 at 7:30 AM | globenewswire.comXOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review VoucherJune 9, 2024 | americanbankingnews.comXOMA (NASDAQ:XOMA) Shares Cross Above 200-Day Moving Average of $22.10June 3, 2024 | businesswire.comLadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin LicenseMay 14, 2024 | globenewswire.comXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQMay 9, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comXOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesApril 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For XOMAApril 25, 2024 | finance.yahoo.comXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)April 25, 2024 | globenewswire.comXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)April 24, 2024 | prnewswire.comActym Therapeutics Appoints Thomas Smart as CEOApril 20, 2024 | finance.yahoo.comXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsApril 3, 2024 | globenewswire.comXOMA Corporation Announces Closing of Tender OfferMarch 21, 2024 | globenewswire.comXOMA Declares Quarterly Preferred Stock DividendsMarch 19, 2024 | globenewswire.comXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.March 13, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 8, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023March 8, 2024 | finance.yahoo.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueMarch 8, 2024 | globenewswire.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueFebruary 28, 2024 | globenewswire.comXOMA to Present at Upcoming Investor Conferences in MarchFebruary 19, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEFebruary 18, 2024 | msn.comCompare with Maple Leaf Green World Inc (4HV0)February 17, 2024 | finance.yahoo.comXOMA Mar 2024 20.000 putFebruary 17, 2024 | finance.yahoo.comXOMA Jun 2024 25.000 callFebruary 16, 2024 | benzinga.comBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate BiopharmaFebruary 16, 2024 | marketwatch.comXOMA Agrees to Acquire Kinnate BiopharmaSee More Headlines Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/13/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CUSIP98419J10 CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees13Year Founded1981Price Target and Rating Average Stock Price Target$57.00 High Stock Price Target$74.00 Low Stock Price Target$40.00 Potential Upside/Downside+127.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,830,000.00 Net Margins-705.23% Pretax Margin-681.69% Return on Equity-26.00% Return on Assets-14.30% Debt Debt-to-Equity Ratio1.39 Current Ratio9.45 Quick Ratio9.45 Sales & Book Value Annual Sales$4.76 million Price / Sales61.16 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book3.24Miscellaneous Outstanding Shares11,640,000Free Float10,801,000Market Cap$291.12 million OptionableOptionable Beta0.85 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Owen P. Hughes Jr. (Age 49)CEO & Director Comp: $193.75kMr. Thomas M. Burns (Age 50)Senior VP of Finance & CFO Comp: $759.24kMr. Brad Sitko (Age 43)Chief Investment Officer Comp: $867.08kKey CompetitorsProgenics PharmaceuticalsNASDAQ:PGNXSyros PharmaceuticalsNASDAQ:SYRSCue BiopharmaNASDAQ:CUEOsmotica PharmaceuticalsNASDAQ:OSMTInnovivaNASDAQ:INVAView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDBought 8,778 shares on 5/15/2024Ownership: 0.075%Vanguard Group Inc.Sold 15,941 shares on 5/10/2024Ownership: 3.484%BNP Paribas Financial MarketsBought 1,266 shares on 5/1/2024Ownership: 0.030%Bradley SitkoBought 1,500 shares on 10/2/2023Total: $21,375.00 ($14.25/share)Owen HughesBought 1,000 shares on 10/2/2023Total: $13,830.00 ($13.83/share)View All Insider TransactionsView All Institutional Transactions XOMA Stock Analysis - Frequently Asked Questions Should I buy or sell XOMA stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XOMA shares. View XOMA analyst ratings or view top-rated stocks. What is XOMA's stock price target for 2024? 3 Wall Street research analysts have issued 1-year target prices for XOMA's stock. Their XOMA share price targets range from $40.00 to $74.00. On average, they anticipate the company's stock price to reach $57.00 in the next twelve months. This suggests a possible upside of 127.9% from the stock's current price. View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts. How have XOMA shares performed in 2024? XOMA's stock was trading at $18.50 at the beginning of the year. Since then, XOMA stock has increased by 35.2% and is now trading at $25.01. View the best growth stocks for 2024 here. When is XOMA's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our XOMA earnings forecast. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.15. The biotechnology company earned $1.49 million during the quarter, compared to analysts' expectations of $0.96 million. XOMA had a negative trailing twelve-month return on equity of 26.00% and a negative net margin of 705.23%. What is John Varian's approval rating as XOMA's CEO? 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO). Who are XOMA's major shareholders? XOMA's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.48%), Price T Rowe Associates Inc. MD (0.08%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Owen Hughes and Thomas M Burns. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XOMA) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.